OKLAHOMA MEDICAL RESEARCH FOUNDATION
Patent Owner
Stats
- 109 US PATENTS IN FORCE
- 7 US APPLICATIONS PENDING
- Oct 05, 2017 most recent publication
Details
- 109 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 2,678 Total Citation Count
- Oct 29, 1987 Earliest Filing
- 127 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2017/0247,462 TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMYELITIS OPTICAJun 29, 15Aug 31, 17[A61K, G01N, C07K]
2014/0128,276 CYTOKINE PROFILES AS METHODS FOR DIAGNOSIS AND PROGNOSIS OF IRRITABLE BOWEL SYNDROMEJan 13, 12May 08, 14[G01N]
2013/0197,028 nAChRalpha7 Agonists and nAChRalpha7 Antagonists for Treating Ulcerative Colitis (UC) and Crohn's Disease (CD)Jun 24, 11Aug 01, 13[A61K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9556266 Methods of treating sickle cell disease with anti-P-selectin antibodiesFeb 01, 13Jan 31, 17[A61K, C07K]
9511095 Cells treated by in vitro fucosylation and methods of production and use thereofMay 14, 13Dec 06, 16[A61K, C12N]
9453204 Production of pluripotent cells through inhibition of bright/ARID3a functionJul 10, 09Sep 27, 16[C12N]
9200324 Biomarkers and methods for measuring and monitoring inflammatory disease activityOct 15, 10Dec 01, 15[C12Q, G01N, G06F]
9127072 Methods of treating hemophilia using monoclonal antibodies against activated protein CNov 29, 11Sep 08, 15[A61K, C07K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2015/0258,168 MODULATION OF PODOPLANIN MEDIATED PLATELET ACTIVATIONAbandonedSep 12, 13Sep 17, 15[A61K, C12N, C07K]
2015/0098,940 Biomarkers for Systemic Lupus Erythematosus Disease Activity, and Intensity and FlareAbandonedOct 02, 14Apr 09, 15[G01N]
2014/0302,013 PREDICTING AND DIAGNOSING PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSAbandonedApr 08, 14Oct 09, 14[C12Q]
2014/0066,488 Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's DiseaseAbandonedAug 28, 13Mar 06, 14[A61K, C07D, C07C]
2014/0005,071 Method of Using Cytokine Assays to Diagnose, Treat, and Evaluate Inflammatory DiseaseAbandonedSep 03, 13Jan 02, 14[G01N]
2013/0303,391 METHODS FOR DIAGNOSIS AND PROGNOSIS OF INFLAMMATORY BOWEL DISEASE USING CYTOKINE PROFILESAbandonedSep 14, 11Nov 14, 13[G01N]
2013/0225,694 COMPOSITIONS AND METHODS OF INHIBITING RETINAL DEGENERATIONAbandonedFeb 25, 13Aug 29, 13[A61K]
2013/0209,366 Glutathione-Lanthionine Compounds and Methods Related TheretoAbandonedAug 24, 11Aug 15, 13[A61K, C07K]
2013/0073,213 Gene Expression-Based Differential Diagnostic Model for Rheumatoid ArthritisAbandonedSep 17, 12Mar 21, 13[G06F]
2012/0258,883 METHOD OF USING CYTOKINE ASSAYS TO DIAGNOSE, TREAT, AND EVALUATE INFLAMMATORY AND AUTOIMMUNE DISEASESAbandonedMay 09, 12Oct 11, 12[C40B]
2012/0197,059 UBIQUITIN INTERACTING MOTIF PEPTIDES AS CANCER THERAPEUTICSAbandonedJan 31, 12Aug 02, 12[A61K, A61P, A61N]
2012/0116,685 Methods, System, And Medium For Associating Rheumatoid Arthritis Subjects With Cardiovascular DiseaseAbandonedApr 05, 10May 10, 12[G06F]
2011/0212,096 ANTI-P-SELECTIN ANTIBODIES AND METHODS OF THEIR USE AND IDENTIFICATIONAbandonedDec 21, 10Sep 01, 11[A61K, C07H, C12N, A61P, C07K]
2011/0183,891 Methods and Compositions for Inhibiting Fungal Infection and DiseaseAbandonedDec 14, 10Jul 28, 11[A61K, C12N, A61P, C07K]
2011/0110,954 Anthrax compositions and methods of use and productionAbandonedSep 13, 10May 12, 11[A61K, G01N, A61P, C07K]
7829669 Catalytically active recombinant memapsin and methods of use thereofExpiredAug 03, 07Nov 09, 10[C07K]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
